标题
Genetically engineered mouse models of PI3K signaling in breast cancer
作者
关键词
-
出版物
Molecular Oncology
Volume 7, Issue 2, Pages 146-164
出版商
Wiley
发表日期
2013-02-11
DOI
10.1016/j.molonc.2013.02.003
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- (2013) J. Lin et al. CLINICAL CANCER RESEARCH
- Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
- (2012) Libero Santarpia et al. BREAST CANCER RESEARCH AND TREATMENT
- Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
- (2012) A Gallardo et al. BRITISH JOURNAL OF CANCER
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
- (2012) Taru Muranen et al. CANCER CELL
- Life in the Fast Lane: Mammalian Disease Models in the Genomics Era
- (2012) Lukas E. Dow et al. CELL
- Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models
- (2012) P. J. Roberts et al. CLINICAL CANCER RESEARCH
- Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition
- (2012) Dimitrios Zardavas et al. CURRENT OPINION IN ONCOLOGY
- The p110 and p110 isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis
- (2012) T. Utermark et al. GENES & DEVELOPMENT
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors
- (2012) James F. Blake et al. JOURNAL OF MEDICINAL CHEMISTRY
- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
- (2012) B. R. Davies et al. MOLECULAR CANCER THERAPEUTICS
- The landscape of cancer genes and mutational processes in breast cancer
- (2012) Philip J. Stephens et al. NATURE
- The clonal and mutational evolution spectrum of primary triple-negative breast cancers
- (2012) Sohrab P. Shah et al. NATURE
- Whole-genome analysis informs breast cancer response to aromatase inhibition
- (2012) Matthew J. Ellis et al. NATURE
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
- (2012) Zhao Chen et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Expression of tumour-specific antigens underlies cancer immunoediting
- (2012) Michel DuPage et al. NATURE
- Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system
- (2012) Metamia Ciampricotti et al. NATURE MEDICINE
- Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
- (2012) Karin Beelen et al. Nature Reviews Clinical Oncology
- Patient-derived tumour xenografts as models for oncology drug development
- (2012) John J. Tentler et al. Nature Reviews Clinical Oncology
- The functions and regulation of the PTEN tumour suppressor
- (2012) Min Sup Song et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Conditional activation of Pik3ca H1047R in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations
- (2012) W Yuan et al. ONCOGENE
- Physiological Levels of Pik3caH1047R Mutation in the Mouse Mammary Gland Results in Ductal Hyperplasia and Formation of ERα-Positive Tumors
- (2012) Anjali Tikoo et al. PLoS One
- Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo
- (2012) Yuanxi Zhu et al. TUMOR BIOLOGY
- The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ- Myc Lymphoma by Restoring Oncogene-Induced Senescence
- (2012) Meaghan Wall et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- Evolutionary Pathways in BRCA1-Associated Breast Tumors
- (2012) Filipe C. Martins et al. Cancer Discovery
- The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer
- (2012) Amaury G. Dumont et al. Chinese Journal of Cancer
- Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor
- (2011) Inma M. Berenjeno et al. BIOCHEMICAL JOURNAL
- Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models
- (2011) Ivo J. Huijbers et al. BIOESSAYS
- Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes
- (2011) Sandrine Boyault et al. BREAST CANCER RESEARCH AND TREATMENT
- Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
- (2011) E. Razis et al. BREAST CANCER RESEARCH AND TREATMENT
- Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
- (2011) Timothy A. Yap et al. CA-A CANCER JOURNAL FOR CLINICIANS
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
- (2011) Rafael B. Blasco et al. CANCER CELL
- Cooperation between Pik3ca and p53 Mutations in Mouse Mammary Tumor Formation
- (2011) J. R. Adams et al. CANCER RESEARCH
- Luminal Expression of PIK3CA Mutant H1047R in the Mammary Gland Induces Heterogeneous Tumors
- (2011) D. S. Meyer et al. CANCER RESEARCH
- Nuclear PTEN Regulates the APC-CDH1 Tumor-Suppressive Complex in a Phosphatase-Independent Manner
- (2011) Min Sup Song et al. CELL
- A Rapid and Scalable System for Studying Gene Function in Mice Using Conditional RNA Interference
- (2011) Prem K. Premsrirut et al. CELL
- Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
- (2011) Phuong K. Morrow et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer
- (2011) Daniel P. Sutherlin et al. JOURNAL OF MEDICINAL CHEMISTRY
- GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
- (2011) J. J. Wallin et al. MOLECULAR CANCER THERAPEUTICS
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. MOLECULAR CANCER THERAPEUTICS
- A continuum model for tumour suppression
- (2011) Alice H. Berger et al. NATURE
- Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis
- (2011) H Nikki March et al. NATURE GENETICS
- Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms
- (2011) Pixu Liu et al. NATURE MEDICINE
- Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes
- (2011) Yoko S DeRose et al. NATURE MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer
- (2011) Jatin Roper et al. PLoS One
- Akt1 Is Essential for Postnatal Mammary Gland Development, Function, and the Expression of Btn1a1
- (2011) Jessica LaRocca et al. PLoS One
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
- (2011) A. Chakrabarty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
- (2011) V. S. Rodrik-Outmezguine et al. Cancer Discovery
- Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
- (2011) David G. DeNardo et al. Cancer Discovery
- PTEN, PIK3CA, p-AKT, and p-p70S6K Status
- (2010) Francisco J. Esteva et al. AMERICAN JOURNAL OF PATHOLOGY
- Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
- (2010) Guy Jerusalem et al. BREAST CANCER RESEARCH AND TREATMENT
- 4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
- (2010) Qing-Bai She et al. CANCER CELL
- Hot-spot mutations in p110α of phosphatidylinositol 3-kinase (PI3K): Differential interactions with the regulatory subunit p85 and with RAS
- (2010) Li Zhao et al. CELL CYCLE
- PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer
- (2010) J. Dupont Jensen et al. CLINICAL CANCER RESEARCH
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab
- (2010) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis
- (2010) Christopher W. Chiu et al. JOURNAL OF CLINICAL ONCOLOGY
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation
- (2010) Vallian Sadeq et al. MEDICAL ONCOLOGY
- Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
- (2010) N. A. O'Brien et al. MOLECULAR CANCER THERAPEUTICS
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
- (2010) Mallika Singh et al. NATURE BIOTECHNOLOGY
- Subtle variations in Pten dose determine cancer susceptibility
- (2010) Andrea Alimonti et al. NATURE GENETICS
- The emerging mechanisms of isoform-specific PI3K signalling
- (2010) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers
- (2010) C. G. Fedele et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
- (2010) S. Loi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PiggyBac Transposon Mutagenesis: A Tool for Cancer Gene Discovery in Mice
- (2010) R. Rad et al. SCIENCE
- Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
- (2009) Juan M. García-Martínez et al. BIOCHEMICAL JOURNAL
- Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma
- (2009) Jennifer Dunlap et al. BREAST CANCER RESEARCH AND TREATMENT
- Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling
- (2009) Christina Gewinner et al. CANCER CELL
- Akt1 and Akt2 Play Distinct Roles in the Initiation and Metastatic Phases of Mammary Tumor Progression
- (2009) R. L. Dillon et al. CANCER RESEARCH
- Differential Enhancement of Breast Cancer Cell Motility and Metastasis by Helical and Kinase Domain Mutations of Class IA Phosphoinositide 3-Kinase
- (2009) H. Pang et al. CANCER RESEARCH
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
- (2009) K. Yu et al. CANCER RESEARCH
- Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors
- (2009) Ana M. Mendes-Pereira et al. EMBO Molecular Medicine
- PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis
- (2009) Babette Schade et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
- (2009) Carson C. Thoreen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras
- (2009) Jennifer O. Lauchle et al. NATURE
- A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma
- (2009) Vincent W Keng et al. NATURE BIOTECHNOLOGY
- Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction
- (2009) Daming Gao et al. NATURE CELL BIOLOGY
- A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites
- (2009) Anthony G Uren et al. Nature Protocols
- Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
- (2009) A. C. Faber et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition
- (2008) Neil E. Torbett et al. BIOCHEMICAL JOURNAL
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- Distinct roles of the three Akt isoforms in lactogenic differentiation and involution
- (2008) Ioanna G. Maroulakou et al. JOURNAL OF CELLULAR PHYSIOLOGY
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- PTEN-deficient cancers depend on PIK3CB
- (2008) S. Wee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now